A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.

Condition studied

Hematological Malignancies

Investigational medicinal product(s)

Eligibility

Primary endpoint

1. Number of Participants Reporting Dose-limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Deaths in Participants With Hematological Malignancies. Adverse events (AEs) will be graded using NCI-CTCAE version 5.0., 2. Complete Response in Participants With Hematological Malignancies by Blinded Independent Central Review (Cohort A Randomization Optimization Phase, Cohort A Phase 2). Complete Response (CR) is defined as participants with CR as measured by Blinded Independent Central Review assessment., 3. Complete Response in Participants With Hematological Malignancies by Investigator Assessment (Cohort B Randomization Optimization Phase). Complete Response (CR) is defined as participants with CR as measured by investigator assessment.